ATE412897T1 - Diagnoseverfahren für atherosklerose - Google Patents

Diagnoseverfahren für atherosklerose

Info

Publication number
ATE412897T1
ATE412897T1 AT04753487T AT04753487T ATE412897T1 AT E412897 T1 ATE412897 T1 AT E412897T1 AT 04753487 T AT04753487 T AT 04753487T AT 04753487 T AT04753487 T AT 04753487T AT E412897 T1 ATE412897 T1 AT E412897T1
Authority
AT
Austria
Prior art keywords
ligand
plaques
atherosclerosis
catheter
conjugate
Prior art date
Application number
AT04753487T
Other languages
English (en)
Inventor
Philip Low
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE412897T1 publication Critical patent/ATE412897T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04753487T 2003-05-30 2004-05-27 Diagnoseverfahren für atherosklerose ATE412897T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47473103P 2003-05-30 2003-05-30

Publications (1)

Publication Number Publication Date
ATE412897T1 true ATE412897T1 (de) 2008-11-15

Family

ID=33551506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04753487T ATE412897T1 (de) 2003-05-30 2004-05-27 Diagnoseverfahren für atherosklerose

Country Status (8)

Country Link
US (3) US7977058B2 (de)
EP (1) EP1629281B1 (de)
JP (1) JP4680185B2 (de)
AT (1) ATE412897T1 (de)
CA (1) CA2527196C (de)
DE (1) DE602004017452D1 (de)
ES (1) ES2317010T3 (de)
WO (1) WO2004110250A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635910A (zh) 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
WO2003003975A2 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
ATE412897T1 (de) 2003-05-30 2008-11-15 Purdue Research Foundation Diagnoseverfahren für atherosklerose
CN101128152A (zh) 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
EP1904183B1 (de) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmazeutische Zusammensetzung zur Behandlung von Arthrose
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
US20070208400A1 (en) * 2006-03-01 2007-09-06 The General Hospital Corporation System and method for providing cell specific laser therapy of atherosclerotic plaques by targeting light absorbers in macrophages
US20100226967A1 (en) * 2006-05-23 2010-09-09 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
US8078264B2 (en) * 2006-07-11 2011-12-13 Case Western Reserve University Intra-operative molecular imaging
CA2668197A1 (en) * 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
WO2008075349A1 (en) * 2006-12-18 2008-06-26 Immune System Key Ltd. Therapeutic methods using a thymus peptide
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
CA2688308A1 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9271653B2 (en) * 2007-06-12 2016-03-01 Case Western Reserve University Intra-operative molecular imaging
WO2010102238A1 (en) * 2009-03-05 2010-09-10 Purdue Research Foundation Method for early imaging of atherosclerosis
JP5896568B2 (ja) * 2010-11-08 2016-03-30 国立大学法人 鹿児島大学 動脈硬化又は動脈硬化性疾患の治療剤、及び動脈硬化又は動脈硬化性疾患の診断薬
RU2480143C1 (ru) * 2012-02-17 2013-04-27 Федеральное государственное бюджетное учреждение науки Институт общей физики им. А.М. Прохорова Российской академии наук (ИОФ РАН) Способ обнаружения атеросклеротических бляшек с измененной метаболической активностью
KR101477498B1 (ko) * 2014-02-21 2014-12-30 고려대학교 산학협력단 죽상동맥경화 영상화용 조성물 및 이를 이용한 죽상동맥경화 진단방법
US11262309B2 (en) * 2018-07-11 2022-03-01 Advanced Cytometry Instrumentation Systems, Llc Methods for lipid measurement in cells

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738535A (en) * 1902-04-22 1903-09-08 Julien V Frederick Feed-cutter.
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4817601A (en) * 1985-03-06 1989-04-04 C. R. Bard, Inc. Catheter system for controlled removal by radiant energy of biological obstructions
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4641650A (en) * 1985-03-11 1987-02-10 Mcm Laboratories, Inc. Probe-and-fire lasers
US4718417A (en) * 1985-03-22 1988-01-12 Massachusetts Institute Of Technology Visible fluorescence spectral diagnostic for laser angiosurgery
US4850351A (en) * 1985-05-22 1989-07-25 C. R. Bard, Inc. Wire guided laser catheter
US4917084A (en) * 1985-07-31 1990-04-17 C. R. Bard, Inc. Infrared laser catheter system
US5336506A (en) * 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
US4785806A (en) * 1987-01-08 1988-11-22 Yale University Laser ablation process and apparatus
CA1340527C (en) * 1988-05-31 1999-05-04 Lidia Vallarino Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
ATE133545T1 (de) * 1988-12-21 1996-02-15 Massachusetts Inst Technology Verfahren für laserinduzierte fluoreszenz von gewebe
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
RU2123338C1 (ru) 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
AU8007791A (en) 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
US5576305A (en) * 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5275594A (en) * 1990-11-09 1994-01-04 C. R. Bard, Inc. Angioplasty system having means for identification of atherosclerotic plaque
US5399338A (en) * 1991-05-01 1995-03-21 University Of New Mexico Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5217456A (en) * 1992-02-24 1993-06-08 Pdt Cardiovascular, Inc. Device and method for intra-vascular optical radial imaging
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6649143B1 (en) * 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
FI98765C (fi) 1995-01-16 1997-08-11 Erkki Soini Virtaussytometrinen menetelmä ja laite
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6507747B1 (en) * 1998-12-02 2003-01-14 Board Of Regents, The University Of Texas System Method and apparatus for concomitant structural and biochemical characterization of tissue
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
AU7123500A (en) 1999-09-08 2001-07-09 Sloan-Kettering Institute For Cancer Research Polysialic acid-klh conjugate vaccine
IL131887A0 (en) 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US6782289B1 (en) * 1999-10-08 2004-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for characterizing lesions in blood vessels and other body lumens
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
CN102805868A (zh) * 2000-03-31 2012-12-05 普渡研究基金会 用配体-免疫原缀合物治疗的方法
US6780984B2 (en) * 2000-07-17 2004-08-24 Northwestern University Method for prognosing cancer and the proteins involved
BR0207521A (pt) * 2001-02-23 2004-06-01 Bristol Myers Squibb Pharma Co Antagonistas rotulados de receptores de removedores macrófagos para a geração de imagens de aterosclerose e placa vulnerável
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CN1635910A (zh) * 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
CA2482924A1 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
ATE448799T1 (de) * 2002-05-06 2009-12-15 Endocyte Inc Folatrezeptor gerichtete bildgebende konjugate
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
WO2004044227A2 (en) 2002-11-07 2004-05-27 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
EP2517730A3 (de) 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
WO2004100983A2 (en) * 2003-05-06 2004-11-25 Purdue Research Foundation, Inc. Treatment of lupus targeting the macrophages or the folate receptor
ATE412897T1 (de) 2003-05-30 2008-11-15 Purdue Research Foundation Diagnoseverfahren für atherosklerose
AU2004291503A1 (en) 2003-11-13 2005-06-02 Janssen Pharmaceutica N.V. Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
US20050153371A1 (en) 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules
WO2005087275A2 (en) 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8486371B2 (en) 2004-09-17 2013-07-16 The Regents Of The University Of Michigan Quantitative two-photon flow cytometry
US7491502B2 (en) * 2004-12-17 2009-02-17 The General Hospital Corporation In vivo flow cytometry system and method
CN101128152A (zh) 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
CA2593256A1 (en) 2005-01-05 2006-07-13 Board Of Regents, The University Of Texas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
WO2007001466A2 (en) 2005-06-14 2007-01-04 Kung, Hank, F. Peptidomimetic somatostatin receptor subtype 2 ligands and pet imaging agents
EP1904183B1 (de) * 2005-07-05 2014-10-15 Purdue Research Foundation Pharmazeutische Zusammensetzung zur Behandlung von Arthrose
US8795633B2 (en) * 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
CA2668197A1 (en) * 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
CA2688308A1 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US20090012009A1 (en) * 2007-06-01 2009-01-08 Low Philip S Composition and Method for Treating Inflammatory Disease
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2010102238A1 (en) 2009-03-05 2010-09-10 Purdue Research Foundation Method for early imaging of atherosclerosis

Also Published As

Publication number Publication date
EP1629281A4 (de) 2006-08-30
JP2006526642A (ja) 2006-11-24
JP4680185B2 (ja) 2011-05-11
US20110189086A1 (en) 2011-08-04
DE602004017452D1 (de) 2008-12-11
CA2527196A1 (en) 2004-12-23
US8808998B2 (en) 2014-08-19
US7977058B2 (en) 2011-07-12
ES2317010T3 (es) 2009-04-16
EP1629281A2 (de) 2006-03-01
EP1629281B1 (de) 2008-10-29
US20130101519A1 (en) 2013-04-25
US20050244336A1 (en) 2005-11-03
WO2004110250A2 (en) 2004-12-23
CA2527196C (en) 2012-10-16
US8383354B2 (en) 2013-02-26
WO2004110250A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
ATE412897T1 (de) Diagnoseverfahren für atherosklerose
EP1973503B1 (de) Sauerstoffsensor zur internen überwachung von gewebesauerstoff in vivo
SG126677A1 (en) Method and device for measuring blood sugar level
EP1149555A3 (de) Fluoreszierendes Endoskopgerät
US20080296514A1 (en) System and method for noninvasively monitoring conditions of a subject
WO2009061367A3 (en) Optical sensor for determining the concentration of an analyte
WO2003075745A3 (en) Detection, diagnosis, and monitoring of a medical condition or disease with artificial olfactometry
WO2001059423A3 (en) Multiphoton excitation through optical fibers for fluorescence spectroscopy
ATE291878T1 (de) Verfahren zur vermeidung von fluoreszenzlöschung
WO2002021074A3 (en) Optical amplification in coherence reflectometry
WO2007117839A3 (en) Method and apparatus for using an optical hemodynamic sensor to identify an unstable arrhythmia
MXPA05007067A (es) Sistema de medicion de analitos que previene la reutilizacion de una tira de prueba.
FR2753897B1 (fr) Dispositif pour le diagnostic endoscopique photodynamique de tissu tumoral
IL155349A0 (en) Analyte concentration determination devices and methods of using the same
WO2003030726A1 (en) Method for automatically detecting, and treating or sampling object portion such as affected portion and its apparatus
DK1686899T3 (da) Ultralydledet sondeindretning
EP1127265B1 (de) Verfahren zur nichtinvasiven abbildung der multidimensionalen verteilung von sauerstoff und vorrichtung dafür
US20180317822A1 (en) Noninvasive optical in-vivo determining of glucose concentration in flowing blood
DE602006008774D1 (de) Kanüleneinführungssystem
WO2004093705A3 (en) Assembly for breast immobilization
JP2002345953A (ja) 静脈検出装置
JP2011232320A (ja) 生体内物質検出用プローブ、および該生体内物質検出用プローブを用いた生体内物質検出装置
WO2000042905A3 (en) Method and apparatus for noninvasive quantitative measurement of blood analytes
US10925528B2 (en) Depth scanning oxygen sensor
DE60109741T8 (de) Verfahren zur vermeidung von fluoreszenzlöschung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties